Why Biotech Should Develop a Market Access Strategy from Early On & How to Do It

June 24, 2020 12:00 PM - 1:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 6/24/2020 12:00:00 PM 6/24/2020 1:00:00 PM Why Biotech Should Develop a Market Access Strategy from Early On & How to Do It

Having a clear, board-backed market access strategy from early on is essential to a company’s success. It provides a critical lever to use with regulators and payers to realize the full clinical and commercial potential of your assets, and the value of your product(s) and company. It will also ensure that your therapies benefit as many patients as possible. As governments increasingly scrutinize drug pricing and healthcare costs, and payers and regulators are focused on differentiated treatments that maximize value and minimize costs, its importance grows in significance.

Our expert panel will walk you through the fundamentals of creating and executing on a market access strategy, plan from preclinical through commercialization, and provide insights as how to best go about it whether you are a starving start-up, a high profile pre-commercial biotechm, or an established multi-national company.


Who will benefit from this forum:

- Early stage companies focused on proving their science and attracting investors
- Later stage companies who want to maximize their value at exit or at first product launch

Sponsored by the MassBio MarComm and Commercial working group.

Webinar, click "live-stream" button to view
Reputation & Risk Management Strategist, Syneos Health
Miriam Kalnicki has nearly 20 years of experience in healthcare, consulting and client management. At Syneos Health, Miriam helps clients address complex business challenges through customized communications strategies, designed to resonate with core stakeholders. As one of the team’s leaders in value communications, Miriam is expert in issues of pricing & access, public health, safety and regulation. Miriam has worked with clients—from small-to-mid-sized biotechs to multinational pharmaceuticals—helping them effectively disclose price at FDA approval, prepare for market access challenges, undergo value framework assessments like ICER reviews and manage risk around routine price increases. Miriam’s success is derived from a deep understanding of the American healthcare system, and the goals, abilities and shortcomings of its key players. Prior to Syneos, Miriam used that understanding to deliver innovative solutions to some of the industry’s toughest challenges. At the health tech company SocialWellth, Miriam led product innovation and program development, providing solutions to hospital and payer clients. Prior to SocialWellth, Miriam worked helped launch Happtique, a prescriptive digital health and patient engagement platform built out of the New York Hospital Association Ventures arm. As a strategic consultant, Miriam focused on a market and operations strategy for consumer products, and spearheaded initiatives to change business operations based on changing consumer perceptions and purchasing habits. She spent 5 years in government relations, where her responsibilities included program management for pharmaceutical companies doing business in Latin America and the Caribbean. Miriam has a BA from Barnard College and an MBA from Georgetown University.